The Relationship between T950C Polymorphism in the Promoter Region of Osteoprotegerin Gene and Type 2 Diabetes with Osteoporosis in Kunming Area
-
摘要:
目的 研究护骨素(OPG)基因启动子区T950C多态性与昆明地区2型糖尿病(T2DM)伴骨质疏松症的关系,探讨T2DM伴骨质疏松症发病的遗传易感因素。 方法 (1)采用聚合酶链反应(PCR-RFLP)技术,检测T2DM无骨质疏松组(A组)61例,T2DM合并骨量减少组(B组)111例,T2DM伴骨质疏松组(C组)65例,OPG基因T950C的基因型,对3组人群的OPG基因T950C进行多态性分析;(2)比较3组患者性别、年龄、糖尿病病程、血压、身高、体重、体重指数(BMI)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血钙、血脂、血尿酸(UA)、维生素D浓度、雌激素、睾酮水平,超敏C-反应蛋白(Hs-CRP)、纤维蛋白原(FIB),口服葡萄糖耐量(OGTT)-0h、2h血糖,0h、2h胰岛素(INS)水平,胰岛素抵抗指数(HOMA-IR)临床指标;(3)比较OPG基因T950C不同基因型间骨密度的差异;(4)将OPG基因T950C的基因型及组间具有统计学差异的指标进行多因素logistic回归分析。 结果 (1)昆明地区T2DM和T2DM伴骨质疏松症患者,OPG基因T950C的基因型以TC型为主;(2)3组OPG基因T950C的基因型的频率及等位基因频率差异均无统计学意义(P > 0.05);(3)3组患者年龄、身高、体重、BMI比较,差异有统计学意义(P < 0.05),且两两比较,差异有统计学意义(P < 0.05);(4)OPG基因T950C的三种基因型比较,各部位的骨密度差异无统计学意义(P > 0.05);(5)多因素Logistic回归分析显示:年龄、吸烟可进入回归方程,而OPGOPG基因T950C的基因型未进入回归方程。 结论 (1)昆明地区T2DM和T2DM伴骨质疏松症患者,OPG基因T950C的基因型以TC型为主;(2)3组OPG基因T950C的基因型的频率及等位基因频率差异均无统计学意义,OPG基因T950C的三种基因型比较,各部位的骨密度差异无统计学意义,OPG基因T950C的基因型可能与昆明地区T2DM及T2DM伴骨质疏松症的遗传易感性无关;(3)年龄、吸烟是昆明地区T2DM伴骨质疏松患者的独立危险因素。 -
关键词:
- 护骨素(OPG) /
- 基因启动子区T950C多态性 /
- 2型糖尿病 /
- 骨质疏松症
Abstract:Objective To study the relationship between the T950C polymorphism in the promoter region of the osteoprotegerin (OPG) gene and type 2 diabetes mellitus (T2DM) with osteoporosis in Kunming, and to explore the genetic susceptibility factors of T2DM with osteoporosis. Methods (1) The polymerase chain reaction (PCR-RFLP) technique was used to detect the OPG gene T950C polymorphism about 61 cases in the T2DM without osteoporosis group (group A), 111 cases in the T2DM combined with osteopenia group (group B), and T2DM with osteoporosis group ( Group C) 65 cases. The OPG gene T950C polymorphism was analyzed in the 3 groups of people. (2) We compare the 3 groups of patients' clinical indicators including gender, age, diabetes course, blood pressure, height, weight, body mass index ( BMI), fasting blood glucose (FPG), glycosylated hemoglobin (HbA1c), blood calcium, blood lipids, blood uric acid (UA), vitamin D concentration, estrogen, testosterone levels, high-sensitivity C-reactive protein (Hs-CRP), fibrin Original (FIB), oral glucose tolerance (OGTT) -0h, 2h blood glucose, 0h, 2h insulin (INS) levels and insulin resistance index (HOMA-IR). (3) We compared the bone mineral density among different genotypes of OPG gene T950C. (4) Multivariate logistic regression analysis was performed on the genotype of OPG gene T950C and the indicators with statistical differences between groups. Results (1) In patients with T2DM and T2DM with osteoporosis in Kunming, the main genotype of OPG gene T950C was TC. (2) There was no statistical difference in the genotype frequency and allele frequency of the three groups of OPG gene T950C (P > 0.05). (3) The comparison of age, height, weight, and BMI of the three groups of patients, the difference was statistically significant (P < 0.05), and the differences were statistically significant in each other (P < 0.05). (4) Comparing the three genotypes of OPG gene T950C, there was no statistically significant difference in bone mineral density (P > 0.05). (5) Multivariate logistic regression analysis showed that age and somking can enter the regression equation, while OPG gene T950C genotype did not enter the regression equation. Conclusions (1) In patients with T2DM and T2DM with osteoporosis in Kunming, the genotype of OPG gene T950C is mainly TC type. (2) There is no statistical difference in the genotype frequency and allele frequency of the three groups of OPG gene T950C. Comparing the three genotypes of OPG gene T950C, there is no statistically significant difference in bone mineral density. The genotype of OPG gene T950C may have nothing to do with the genetic susceptibility of T2DM and T2DM with osteoporosis in Kunming (3) Age and smoking are independent risk factor for patients with T2DM and osteoporosis in Kunming. -
表 1 DNA提取所需试剂及仪器
Table 1. Required for DNA extraction reagent and instrument
试剂及仪器 来源 DNA提取试剂盒 AXYGEN公司 DNA聚合酶(2×Taq Master Mix) Bioteke公司 引物 昆明硕擎公司合成 普通PCR仪 美国应用生物系统公司:ABI2720 各种规格的离心管、枪尖、PCR管、一次性乳胶手套和口罩 NSET公司 表 2 研究对象的一般资料比较[(
$ \bar x \pm s $ ),M(P25,P75)]Table 2. Comparison of general data of study objects[(
$ \bar x \pm s $ ),M(P25,P75)]指标/分组 A组(61例) B组(111例) C组(65例) 统计量值 P值 性别(男/女)) 46/15 61/50# 15/50*#& 18.286 < 0.001 年龄(岁) 61.65 ± 8.16 64.79 ± 10.15# 66.33 ± 6.77*#& 4.573 0.011* 吸烟(是/否) 24/37 32/79 11/54*# 7.833 0.020* 饮酒(是/否) 17/44 29/82 6/59*#& 8.518 0.014* 绝经年龄(女,岁) 50(48 ,54 ) 50(48 ,52 ) 50(48 ,51 ) −0.744 0.457 糖尿病病程(a) 9.18 ± 7.34 10.11 ± 7.46 8.69 ± 7.36 0.805 0.449 收缩压(mmHg) 126.77 ± 22.50 129.07 ± 19.73 125.77 ± 22.54 0.543 0.582 舒张压(mmHg) 80.77 ± 11.51 78.64 ± 10.27 74.97 ± 12.30*# 4.364 0.014* 身高(m) 167.64 ± 7.32 164.12 ± 8.04# 158.13 ± 7.21*#& 24.880 0.000* 体重(kg) 71.02 ± 11.16 65.85 ± 9.94# 59.07 ± 10.45*#& 20.955 0.000* 体重指数(kg/m2) 25.26 ± 2.77 24.29 ± 2.75# 23.40 ± 3.21*# 6.369 0.002* TC(mmol/L) 4.94 ± 1.59 4.57 ± 1.22 4.90 ± 1.02 2.122 0.122 TG(mmol/L) 2.13(1.32,3.25 ) 1.65(1.19,2.26 ) 1.79(1.30,2.41 ) −2.163 0.051 HDLC(mmol/L) 1.09 ± 0.34 1.15 ± 0.28 1.23 ± 0.31*# 3.410 0.035* LDLC(mmol/L) 2.79 ± 1.14 2.82 ± 0.99 3.15 ± 1.01 2.389 0.094 FPG(mmol/L) 8.63(7.31,12.29 ) 8.55(6.85,11.19 ) 8.13(6.58,10.97 ) −1.297 0.195 HBA1c(%) 8.60 ± 1.91 8.32 ± 2.04 8.06 ± 1.76 1.199 0.303 OGTT-0h(mmol/L) 8.09 ± 2.29 8.25 ± 2.06 8.13 ± 2.71 0.093 0.911 OGTT-2h(mmol/L) 17.86 ± 3.19 18.29 ± 4.60 17.81 ± 4.73 0.223 0.800 INS-0h(mIU/L) 15.36(9.50,21.35 ) 15.64(7.83,32.75 ) 15.23(8.23,25.83 ) −0.426 0.670 INS-2h(mIU/L) 34.79(23.12,58.31 ) 41.12(25.93,67.58 ) 52.49(35.09,81.46 ) −1.300 0.194 HOMR-IR 4.77(2.69,9.08 ) 5.23(2.65,11.2) 4.98(2.37,8.86 ) −0.492 0.623 UA(umol/L) 354.05 ± 86.92 342.32 ± 99.48 314.82 ± 92.09 2.909 0.057 血钙(mmol/L) 2.33 ± 0.11 2.31 ± 0.12 2.32 ± 0.12 0.722 0.487 雌激素
(pmol/L)116.90(80.73,152.44,) 90.42(60.97,140.19) 81.12(58.63,98.22 ) *# −1.949 0.041* 睾酮(nmol/L) 9.13(1.94,14.85 ) 5.17(1.32,12.09 ) 1.57(1.17,2.38 ) *#& −2.281 0.023* 维生素D (ng/ml) 18.15 ± 9.72 16.78 ± 6.16 16.00 ± 5.71 1.403 0.248 Hs-CRP(mg/L) 1.72(0.61,3.02 ) 1.70(0.50,2.69 ) 1.06(0.50,3.16 ) −0.368 0.713 FIB(g/L) 2.89 ± 0.70 2.77 ± 0.64 2.80 ± 0.72 0.599 0.550 *P < 0.05。 表 3 OPG基因T950C基因型分布频率比较[n(%)]
Table 3. OPG gene T950C genotypes distribution frequency comparison [n(%)]
组别/基因型 TT n(%) TC n(%) CC n(%) 合计n χ2 P A组 21(34.4 ) 32(52.5) 8(13.1) 61 B组 37(33.3 ) 57(51.7) 17(15.3) 111 C组 13(19.6) 36(55.4) 16(24.6) 65 合计n 71 125 41 237 5.989 0.200 表 4 OPG基因T950C等位基因分布频率
Table 4. OPGgeneT950C allele frequency distribution
组别/基因型 频数 T C χ2 P A组 122 74 48 B组 222 131 91 C组 130 62 68 合计n 474 267 20 5.519 0.063 表 5 OPG基因T950C基因多态性与T2DM患者BMD的关系(g/cm2)[
$ \bar x \pm s $ ]Table 5. The relationship between the OPGgeneT950C gene polymorphism and BMD of T2DM patients (g/cm2)[
$ \bar x \pm s $ ]指标/分组 TT 组(71例) TC组(125例) CC组(41例) F/Z P 腰1 0.952 ± 0.161 0.944 ± 0.166 0.887 ± 0.155 1.521 0.222 腰2 1.034 ± 0.187 1.021 ± 0.188 0.937 ± 0.171 2.371 0.097 腰3 1.081 ± 0.206 1.066 ± 0.197 0.977 ± 0.171 2.639 0.075 腰4 1.113 ± 0.215 1.082 ± 0.181 1.022 ± 0.226 1.763 0.175 左股骨颈 0.885 ± 0.194 0.873 ± 0.193 0.805 ± 0.158 1.582 0.209 左大粗隆 0.774 ± 0.154 0.759 ± 0.167 0.684 ± 0.142 2.779 0.065 左全髋 0.965 ± 0.150 0.912 ± 0.268 0.870 ± 0.135 1.514 0.224 右股骨颈 0.884 ± 0.156 0.835 ± 0.353 0.773 ± 0.206 1.273 0.283 右大粗隆 0.775 ± 0.149 0.726 ± 0.294 0.659 ± 0.184 1.909 0.152 右全髋 0.959(0.863,1.085) 0.912(0.801,1.043) 0.859(0.721,0.951) 1.096 0.295 表 6 Logistic归分析结果
Table 6. Logistic analysis results
因素 B SE Wald P OR值 95%CI OPG-T950C 0.285 0.365 0.609 0.435 1.330 0.650~2.820 性别 0.364 0.932 0.152 0.696 1.439 0.231~8.947 年龄 0.103 0.036 8.245 0.004 1.108 1.033~1.188 吸烟 2.103 0.913 5.302 0.021 8.190 1.368~49.053 饮酒 −0.990 0.841 1.385 0.239 0.372 0.071~1.933 DBP 0.005 0.022 0.046 0.831 1.005 0.963~1.049 身高 −0.084 0.073 1.318 0.251 0.919 0.797~1.061 体重 −0.017 0.072 0.055 0.814 0.983 0.854~1.132 BMI −0.106 0.205 0.264 0.607 0.900 0.602~1.345 HDL-C 0.500 0.881 0.322 0.570 1.648 0.293~9.265 雌激素 0.001 0.003 0.052 0.819 0.999 0.993~1.005 睾酮 −0.117 0.067 3.042 0.081 0.889 0.7779~1.015 -
[1] 王南飞,陈路. 川北地区老年骨质疏松性骨折临床分析[J]. 川北医学院学报,2015,30(6):864-867. doi: 10.3969/j.issn.1005-3697.2015.06.33 [2] Rakel A,Sheehy O,Rahme E,et al. Osteoporosis among patients with type 1 and type 2 daibetes[J]. Diabetes Metabolism,2008,34(3):193-205. doi: 10.1016/j.diabet.2007.10.008 [3] Franke S,Siggelkow H,Wolf G,et al. Advanced glycation endproducts influence the Mrna expression of RAGE,RANKL and various osteoblastic genes in humanosteoblasts[J]. Arch Physiol Biochen,2007,113(3):154-161. doi: 10.1080/13813450701602523 [4] Botolin S,McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways[J]. J Cell Biochem,2006,99(2):411-417. doi: 10.1002/jcb.20842 [5] GordonGong,Gleb Haynatzki,Vera Haynatzka,et al. Bone miberal density-affecting denes in Africans[J]. J The National Medical Association,2006,98(7):1102-1108. [6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南[J]. 中国糖尿病杂志,2014,22(8):2-42. [7] 中华医学会骨质疏松和骨矿盐分会. 原发性骨质疏松症诊治指南[J]. 中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. doi: 10.3969/j.issn.1674-2591.2011.01.002 [8] Nicodemus K K,Folsom A R. Type 1and type 2 diabetesand incident hip fractures in postmenopausal women[J]. Diabetes Care,2001,24(7):1192-1197. [9] 刘红,马俊岭,侯钦午,等. 上海市北蔡社区青年男性骨密度水平调查[J]. 蚌埠医学院学报,2017,42(12):1668-1669,1673. [10] Lacey D L,Timms E,Tan H L,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[J]. Cell,1998,93(2):165-176. doi: 10.1016/S0092-8674(00)81569-X [11] Kong Y Y,Penninger J M. Molecular control of bone remodeling and osteoporosis. Exp Gerontol[J]. Experimental Gerontology,2000,35(8):947-956. doi: 10.1016/S0531-5565(00)00178-9 [12] Arko B,Prezelj J,Komel R,et al. Sequence variations in theosteoprotegrin gene promoter in patients with postmenopausalosteoporosis[J]. J ClinEndocrinolMetab,2002,87(9):4080. [13] Zaj í ckov á K,Zemanov á A,Hill M,et al. Is A163G polymorphism in theosteoprotegerin gene associated with heel velocity of sound inpostmenopausal women?[J]. Physiol Res,2008,57(Suppl.1):S153-S157. [14] Knudsen S T,Jeppesen P,Poulsen P L,et al. Plasma concentrations ofosteoprotegerin during normo-and hyperglycaemicclamping[J]. Seand J Clin Lab Invest,2007,67(2):135-142. doi: 10.1080/00365510600987728 [15] Suzuki K,Kurose T,Takizawa M,et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus:the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density[J]. Diabetes Res Clin Pract,2005,68(2):117-125. doi: 10.1016/j.diabres.2004.08.006 [16] 郑蓉, 苗懿德, 纪立农, 等. 中国组织工程研究与临床康复[J]. 2011, 15(28): 5292-5294. [17] 曹玉丽,刘晓云,门炳玲,等. 赤峰地区2型糖尿病患者与骨质疏松相关因素分析[J]. 内蒙古医学杂志,2019,51(7):775-781. [18] 姚坤, 侯丽艳, 刘晓芳, 等. 糖尿病性骨质疏松常见危险因素 Meta分析 [ D]. 医药卫生科技2019, 6 ( 16): 8 -9. [19] 汤淑涵,李文静,刘佳瑞,等. 吸烟对男性2型糖尿病患者骨密度与骨生化指标影响[J]. 临床医学,2020,7(12):33-34,38.